Pfizer bought Global Blood Therapeutics Global Blood Therapeutics from 10/5/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Pfizer completed its acquisition of Global Blood Therapeutics for $5.4, or $68.5 per share.

Global Blood Therapeutics

Review

Source:

{source} pictogram

investors.pfizer.com

Vladimir Petenev

News editor

Write your comment first

News feed

SPB Exchange completely stops conducting trading

1/30/24 SPBE

IMCB stock split shifted to the right

1/29/24 GEMA

Cherkizovo's export sales in 2023 increased by 15%

1/29/24 GCHE

Nornickel summarized its performance in 2023

1/29/24 GMKN

Ozon launches Premium banking

1/29/24 OZON

Fesco puts a second vessel on the line between Novorossiysk and India

1/29/24 FESH

Etalon Group opened sales of the third phase of Shagal

1/29/24 ETLN

RusHydro will complete the design of HPPs in the Far East by 2025

1/29/24 HYDR

Delimobil started collecting applications for participation in the IPO

1/29/24 DELI

Rusagro summarized its results for 2023

1/29/24 RAGR